The University of Tokyo · 생화학·유전·분자생물학
유지지 타라마루 교수의 연구실은 주로 당뇨병 치료를 위한 이식성 췌장세포(췌도세포)의 생존율 향상과 임상적 응용을 목표로 하고 있습니다. 핵심 연구는 췌도세포 표면에 고분자 코팅을 통해 혈액 응고나 면역 반응을 억제하는 표면 개질 기술이며, 특히 페닐에틸렌 글리콜(PEG)-지질을 이용한 생체막 형성 및 유로키나제, 헤파린 등의 생체활성 물질을 탑재한 초박막 막 코ating 기술을 개발하고 있습니다. 또한, 세포 간 DNA 하이브리드화를 활용한 생체적합성 마이크로캡슐화 기술을 통해 면역억제제가 필요 없는 생인공 췌장 시스템의 실현 가능성을 탐색하고 있습니다.
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
Surface modification of living cells with natural or synthetic polymers is a powerful and useful tool in biomedical science and engineering. Various functional groups and bioactive substances can be immobilized to the cell surface through covalent conjugation, hydrophobic interaction, or electrostatic interaction. In this review, we provide an overview of the methods and polymers employed in cell surface modification, including: (1) covalent conjugation utilizing amino groups of cell surface pro
Our approach for the improvement of graft survival will be useful in the clinical setting.
Transplantation of islets of Langerhans (islets) is a promising technique for treating insulin-dependent diabetes mellitus (type I). One unresolved issue is early graft loss due to inflammation triggered by blood coagulating on the surface of islets after transplantation into the portal vein. Here, we describe a versatile method for modifying the surface of islets with an ultrathin membrane carrying the fibrinolytic enzyme urokinase or the anticoagulant heparin. The surface of islets was modifie
Surface modification of islets with PEG-lipid or PEG-urokinase is a potential useful technology in the clinical application of islet transplantation.
Ischemic stroke is a major cause of death and disability worldwide and is expected to increase in the future with the aging population. Currently, there are no clinically available treatments for damage sustained during an ischemic stroke, but much research is being conducted in this area. In this review, we will introduce current ischemic stroke treatments along with their limitations, as well as research on potential short and long-term future treatments. There are advantages and disadvantages
Microencapsulation of islets with a semipermeable membrane, i.e., bioartificial pancreas, is a promising way to transplant islets without the need for immunosuppressive therapy for insulin-dependent diabetes mellitus (type I diabetes). However, materials composing a bioartificial pancreas are not ideal and might activate defense reactions against foreign materials. In this study, we propose an original method for microencapsulation of islets with living cells using an amphiphilic poly(ethylene g
